DeepMed Research

Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN2009
Other: placebo

First Posted Date: 2013-07-09

Last Posted Date: 2014-11-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01893528

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Dupilumab

First Posted Date: 2013-05-22

Last Posted Date: 2017-08-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 380

Registration Number: NCT01859988

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Phase 1

Completed

Conditions: Systemic Juvenile Idiopathic Arthritis

Interventions: Drug: rilonacept (IL-1 Trap)
Other: Placebo

First Posted Date: 2013-03-04

Last Posted Date: 2013-03-04

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01803321

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Phase 1

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: REGN1500
Drug: placebo

First Posted Date: 2012-12-17

Last Posted Date: 2016-05-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT01749878

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: Alirocumab
Drug: Placebo
Drug: Ezetimibe

First Posted Date: 2012-11-21

Last Posted Date: 2020-04-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 305

Registration Number: NCT01730053

Locations: 🇪🇸
(2 Locations), Barcelona, Spain
🇲🇽
(3 Locations), Guadalajara, Mexico

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: Alirocumab
Drug: Atorvastatin
Drug: Ezetimibe
Drug: Placebo

First Posted Date: 2012-11-21

Last Posted Date: 2015-08-31

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 355

Registration Number: NCT01730040

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: REGN1400
Drug: Erlotinib
Drug: Cetuximab

First Posted Date: 2012-11-16

Last Posted Date: 2015-04-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT01727869

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Phase 4

Completed

Conditions: Age - Related Macular Degeneration (AMD)

Interventions: Drug: Intravitreal Aflibercept Injection (IAI)

First Posted Date: 2012-11-06

Last Posted Date: 2017-12-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT01722045

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: REGN1033 (SAR391786)
Drug: Placebo

First Posted Date: 2012-11-02

Last Posted Date: 2013-09-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT01720576

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

Phase 3

Completed

Conditions: Heterozygous Familial Hypercholesterolemia

Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)
Drug: Placebo
Drug: alirocumab

First Posted Date: 2012-10-18

Last Posted Date: 2015-10-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 249

Registration Number: NCT01709500

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy